中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 40 Issue 1
Jan.  2024
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(1): 175-180

Current status and prospects of transarterial chemoembolization and its combined regimens in the treatment of hepatocellular carcinoma

DOI: 10.12449/JCH240129

  • Department of Interventional Radiology，The First Affiliated Hospital of Soochow University，Suzhou，Jiangsu 215000，China

Research funding:

The Social Development Program of Jiangsu Province (BE2021648)

More Information
  • Corresponding author: ZHU Xiaoli， zhuxiaoli90@163.com （ORCID： 0000-0002-3507-2018）
  • Received Date: 2023-05-06
  • Accepted Date: 2023-05-17
  • Published Date: 2024-01-23
    Abstract
  • Transarterial chemoembolization （TACE） is currently the primary treatment method for advanced liver cancer. This article elaborates on the current status of application of TACE in hepatocellular carcinoma from the aspects of existing techniques， patient selection， and efficacy assessment and summarizes the research advances and prospects of TACE combined with local treatment and systemic therapy， so as to provide new ideas for clinical practice and experimental studies.

     

    • FullText(HTML)
    • References(53)
  • [1]
    VOGEL A, MEYER T, SAPISOCHIN G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400( 10360): 1345- 1362. DOI: 10.1016/S0140-6736(22)01200-4.
    [2]
    ZHENG RS, QU CF, ZHANG SW, et al. Liver cancer incidence and mortality in China: Temporal trends and projections to 2030[J]. Chin J Cancer Res, 2018, 30( 6): 571- 579. DOI: 10.21147/j.issn.1000-9604.2018.06.01.
    [3]
    YAMADA R, SATO M, KAWABATA M, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma[J]. Radiology, 1983, 148( 2): 397- 401. DOI: 10.1148/radiology.148.2.6306721.
    [4]
    LLOVET JM, REAL MI, MONTAÑA X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial[J]. Lancet, 2002, 359( 9319): 1734- 1739. DOI: 10.1016/S0140-6736(02)08649-X.
    [5]
    LO CM, NGAN H, TSO WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]. Hepatology, 2002, 35( 5): 1164- 1171. DOI: 10.1053/jhep.2002.33156.
    [6]
    CHEN MJ, GUO XJ, SHEN L, et al. Monodisperse CaCO3-loaded gelatin microspheres for reversing lactic acid-induced chemotherapy resistance during TACE treatment[J]. Int J Biol Macromol, 2023, 231: 123160. DOI: 10.1016/j.ijbiomac.2023.123160.
    [7]
    ZHU HD, LI X, JI JS, et al. TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: A multicenter randomized phase II trial[J]. Eur Radiol, 2022, 32( 11): 7335- 7343. DOI: 10.1007/s00330-022-08848-7.
    [8]
    ZHANG W, ZHOU YJ, YAN ZP. Further discussion on the precision TACE therapy[J]. J Interv Radiol, 2021, 30( 10): 971- 975. DOI: 10.3969/j.issn.1008-794X.2021.10.001.

    张雯, 周永杰, 颜志平. 再论精细TACE[J]. 介入放射学杂志, 2021, 30( 10): 971- 975. DOI: 10.3969/j.issn.1008-794X.2021.10.001.
    [9]
    MIYAYAMA S. Ultraselective conventional transarterial chemoembolization: When and how?[J]. Clin Mol Hepatol, 2019, 25( 4): 344- 353. DOI: 10.3350/cmh.2019.0016.
    [10]
    BZEIZI KI, ARABI M, JAMSHIDI N, et al. Conventional transarterial chemoembolization versus drug-eluting beads in patients with hepatocellular carcinoma: A systematic review and meta-analysis[J]. Cancers, 2021, 13( 24): 6172. DOI: 10.3390/cancers13246172.
    [11]
    LIU KL, JIN ZC, HU XL, et al. A biodegradable multifunctional porous microsphere composed of carrageenan for promoting imageable trans-arterial chemoembolization[J]. Int J Biol Macromol, 2020, 142: 866- 878. DOI: 10.1016/j.ijbiomac.2019.10.026.
    [12]
    DURAN R, NAMUR J, PASCALE F, et al. Vandetanib-eluting radiopaque beads: Pharmacokinetics, safety, and efficacy in a rabbit model of liver cancer[J]. Radiology, 2019, 293( 3): 695- 703. DOI: 10.1148/radiol.2019190305.
    [13]
    IRIE T, KURAMOCHI M, TAKAHASHI N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: Measurement of balloon-occluded arterial stump pressure[J]. Cardiovasc Intervent Radiol, 2013, 36( 3): 706- 713. DOI: 10.1007/s00270-012-0476-z.
    [14]
    CHU HH, GWON DI, KIM GH, et al. Balloon-occluded transarterial chemoembolization versus conventional transarterial chemoembolization for the treatment of single hepatocellular carcinoma: A propensity score matching analysis[J]. Eur Radiol, 2023, 33( 4): 2655- 2664. DOI: 10.1007/s00330-022-09284-3.
    [15]
    BUCALAU AM, TANCREDI I, PEZZULLO M, et al. Balloon-occluded chemoembolization for hepatocellular carcinoma: A prospective study of safety, feasibility and outcomes[J]. Hepat Oncol, 2020, 8( 1): HEP31. DOI: 10.2217/hep-2020-0022.
    [16]
    General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.

    国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
    [17]
    ZHONG BY, JIN ZC, CHEN JJ, et al. Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma[J]. J Clin Transl Hepatol, 2023, 11( 2): 480- 489. DOI: 10.14218/JCTH.2022.00293.
    [18]
    PARK JW, CHEN M, COLOMBO M,, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study[J]. Liver Int, 2015, 35( 9): 2155- 2166. DOI: 10.1111/liv.12818.
    [19]
    KUDO M, UESHIMA K, CHAN S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh A liver function: A proof-of-concept study[J]. Cancers, 2019, 11( 8): 1084. DOI: 10.3390/cancers11081084.
    [20]
    WANG QH, XIA DD, BAI W, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study[J]. J Hepatol, 2019, 70( 5): 893- 903. DOI: 10.1016/j.jhep.2019.01.013.
    [21]
    ZHANG S, WANG WS, ZHONG BY, et al. Subsequent treatment after transarterial chemoembolization failure/refractoriness: A review based on published evidence[J]. J Clin Transl Hepatol, 2022, 10( 4): 740- 747. DOI: 10.14218/JCTH.2021.00336.
    [22]
    KUDO M, MATSUI O, IZUMI N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update[J]. Oncology, 2014, 87( Suppl 1): 22- 31. DOI: 10.1159/000368142.
    [23]
    Clinical Guidelines Committee of Chinese College of Interventionalists. Expert consensus on the TACE failure/refractoriness and its subsequent therapies in treating patients with hepatocellular carcinoma[J]. J Intervent Radiol, 2022, 31( 11): 1039- 1044. DOI: 10.3969/j.issn.1008-794X.2022.11.001.

    中国医师协会介入医师分会临床诊疗指南专委会. 肝细胞癌经动脉化疗栓塞抵抗及后续治疗专家共识[J]. 介入放射学杂志, 2022, 31( 11): 1039- 1044. DOI: 10.3969/j.issn.1008-794X.2022.11.001.
    [24]
    JIN ZC, CHEN L, ZHONG BY, et al. Machine-learning analysis of contrast-enhanced computed tomography radiomics predicts patients with hepatocellular carcinoma who are unsuitable for initial transarterial chemoembolization monotherapy: A multicenter study[J]. Transl Oncol, 2021, 14( 4): 101034. DOI: 10.1016/j.tranon.2021.101034.
    [25]
    MENG XP, WANG YC, JU SH, et al. Radiomics analysis on multiphase contrast-enhanced CT: A survival prediction tool in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J]. Front Oncol, 2020, 10: 1196. DOI: 10.3389/fonc.2020.01196.
    [26]
    LENCIONI R, BAERE TD, SOULEN MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data[J]. Hepatology, 2016, 64( 1): 106- 116. DOI: 10.1002/hep.28453.
    [27]
    SERGIO A, CRISTOFORI C, CARDIN R, et al. Transcatheter arterial chemoembolization(TACE) in hepatocellular carcinoma(HCC): The role of angiogenesis and invasiveness[J]. Am J Gastroenterol, 2008, 103( 4): 914- 921. DOI: 10.1111/j.1572-0241.2007.01712.x.
    [28]
    YANG Y, YU HL, QI LY, et al. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: A systematic review and meta-analysis[J]. Int J Hyperthermia, 2022, 39( 1): 455- 465. DOI: 10.1080/02656736.2022.2048095.
    [29]
    WANG L, KE Q, LIN NP, et al. The efficacy of transarterial chemoembolization combined with microwave ablation for unresectable hepatocellular carcinoma: A systematic review and meta-analysis[J]. Int J Hyperthermia, 2019, 36( 1): 1288- 1296. DOI: 10.1080/02656736.2019.1692148.
    [30]
    SHETA E, EL-KALLA F, EL-GHARIB M, et al. Comparison of single-session transarterial chemoembolization combined with microwave ablation or radiofrequency ablation in the treatment of hepatocellular carcinoma: A randomized-controlled study[J]. Eur J Gastroenterol Hepatol, 2016, 28( 10): 1198- 1203. DOI: 10.1097/MEG.0000000000000688.
    [31]
    SHIM SJ, SEONG J, HAN KH, et al. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma[J]. Liver Int, 2005, 25( 6): 1189- 1196. DOI: 10.1111/j.1478-3231.2005.01170.x.
    [32]
    HUO YR, ESLICK GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: A systematic review and meta-analysis[J]. JAMA Oncol, 2015, 1( 6): 756- 765. DOI: 10.1001/jamaoncol.2015.2189.
    [33]
    YOON SM, RYOO BY, LEE SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: A randomized clinical trial[J]. JAMA Oncol, 2018, 4( 5): 661- 669. DOI: 10.1001/jamaoncol.2017.5847.
    [34]
    ZHU KS, CHEN JW, LAI LS, et al. Hepatocellular carcinoma with portal vein tumor thrombus: Treatment with transarterial chemoembolization combined with sorafenib: A retrospective controlled study[J]. Radiology, 2014, 272( 1): 284- 293. DOI: 10.1148/radiol.14131946.
    [35]
    CHUNG GE, LEE JH, KIM HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J]. Radiology, 2011, 258( 2): 627- 634. DOI: 10.1148/radiol.10101058.
    [36]
    LYU N, KONG YN, MU LW, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69( 1): 60- 69. DOI: 10.1016/j.jhep.2018.02.008.
    [37]
    LIU BJ, GAO S, ZHU X, et al. Combination therapy of chemoembolization and hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis compared with chemoembolization alone: A propensity score-matched analysis[J]. Biomed Res Int, 2021, 2021: 6670367. DOI: 10.1155/2021/6670367.
    [38]
    HUANG JJ, HUANG WS, ZHAN MX, et al. Drug-eluting bead transarterial chemoembolization combined with FOLFOX-based hepatic arterial infusion chemotherapy for large or huge hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2021, 8: 1445- 1458. DOI: 10.2147/JHC.S339379.
    [39]
    ZHU ZX, WANG XX, YUAN KF, et al. Transarterial chemoembolization plus iodine-125 implantation for hepatocellular carcinoma: A systematic review and meta-analysis[J]. HPB, 2018, 20( 9): 795- 802. DOI: 10.1016/j.hpb.2018.03.015.
    [40]
    LUO JJ, YAN ZP, LIU QX, et al. Endovascular placement of iodine-125 seed strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein[J]. J Vasc Interv Radiol, 2011, 22( 4): 479- 489. DOI: 10.1016/j.jvir.2010.11.029.
    [41]
    WANG WS, WANG C, SHEN J, et al. Integrated I-125 seed implantation combined with transarterial chemoembolization for treatment of hepatocellular carcinoma with main portal vein tumor Thrombus[J]. Cardiovasc Intervent Radiol, 2021, 44( 10): 1570- 1578. DOI: 10.1007/s00270-021-02887-1.
    [42]
    LENCIONI R, LLOVET JM, HAN GH, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial[J]. J Hepatol, 2016, 64( 5): 1090- 1098. DOI: 10.1016/j.jhep.2016.01.012.
    [43]
    MEYER T, FOX R, MA YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma(TACE ‍2): A randomised placebo-controlled, double-blind, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2017, 2( 8): 565- 575. DOI: 10.1016/S2468-1253(17)30156-5.
    [44]
    KUDO M, UESHIMA K, IKEDA M, et al. Final results of TACTICS: A randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma[J]. Liver Cancer, 2022, 11( 4): 354- 367. DOI: 10.1159/000522547.
    [45]
    PENG ZW, FAN WZ, ZHU BW, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A phase III, randomized clinical trial(LAUNCH)[J]. J Clin Oncol, 2023, 41( 1): 117- 127. DOI: 10.1200/JCO.22.00392.
    [46]
    XIA DD, BAI W, WANG EX, et al. Lenvatinib with or without concurrent drug-eluting beads transarterial chemoembolization in patients with unresectable, advanced hepatocellular carcinoma: A real-world, multicenter, retrospective study[J]. Liver Cancer, 2022, 11( 4): 368- 382. DOI: 10.1159/000523849.
    [47]
    SANGRO B, SAROBE P, HERVÁS-STUBBS S, et al. Advances in immunotherapy for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 8): 525- 543. DOI: 10.1038/s41575-021-00438-0.
    [48]
    LLOVET JM, CASTET F, HEIKENWALDER M, et al. Immunotherapies for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2022, 19( 3): 151- 172. DOI: 10.1038/s41571-021-00573-2.
    [49]
    YANG C, ZHANG HL, ZHANG LM, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2023, 20( 4): 203- 222. DOI: 10.1038/s41575-022-00704-9.
    [50]
    CHENG AL, QIN SK, IKEDA M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022, 76( 4): 862- 873. DOI: 10.1016/j.jhep.2021.11.030.
    [51]
    REN ZG, XU JM, BAI YX, et al. Sintilimab plus a bevacizumab biosimilar(IBI305) versus sorafenib in unresectable hepatocellular carcinoma(ORIENT-32): A randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22( 7): 977- 990. DOI: 10.1016/S1470-2045(21)00252-7.
    [52]
    ZHU HD, LI HL, HUANG MS, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)[J]. Signal Transduct Target Ther, 2023, 8( 1): 58. DOI: 10.1038/s41392-022-01235-0.
    [53]
    HUANG JT, ZHONG BY, JIANG N, et al. Transarterial chemoembolization combined with immune checkpoint inhibitors plus tyrosine kinase inhibitors versus immune checkpoint inhibitors plus tyrosine kinase inhibitors for advanced hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2022, 9: 1217- 1228. DOI: 10.2147/JHC.S386672.
    • Relative Articles

  • Relative Articles

    [1]Jiarui YANG, Jianxin JIANG. An excerpt of EASL clinical practice guidelines on the management of hepatocellular carcinoma（2024 edition）[J]. Journal of Clinical Hepatology, 2025, 41(2): 234-239. doi: 10.12449/JCH250207
    [2]Lijuan LONG, Zongyu WANG, Yali ZHAO, Chuanfu QIN, Hua QIU. Research advances in traditional Chinese medicine for the treatment of hepatocellular carcinoma by regulating immune cells[J]. Journal of Clinical Hepatology, 2025, 41(2): 349-358. doi: 10.12449/JCH250223
    [3]Yue YANG, Siyu XU, Jue WANG, Shilin DU, Chunlei ZHANG, Haiyan SONG. Mechanism of action of cinobufotalin in inhibiting lung metastasis of hepatocellular carcinoma by regulating AKT-mediated epithelial-mesenchymal transition in a nude mouse model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1840-1847. doi: 10.12449/JCH240919
    [4]Yuan DUAN, Ting ZHANG, Jing ZHANG, Guiwen GUAN, Jingzhou WANG, Xiangmei CHEN. Expression of AU-rich element RNA-binding factor 1 in hepatocellular carcinoma and its value in prognostic evaluation[J]. Journal of Clinical Hepatology, 2024, 40(9): 1833-1839. doi: 10.12449/JCH240918
    [5]Zheng SONG, Wei LUO, Xiujuan CHANG, Yongping YANG. Construction of a novel disulfidptosis-related prognostic model for patients with hepatocellular carcinoma based on bioinformatics analysis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1822-1832. doi: 10.12449/JCH240917
    [6]Changwang ZHANG, Ninghan WU, Cong WANG, Zheng ZHENG, Siming GAO, Changpeng ZOU, Sujing ZHANG, Na LI. Efficacy and safety of cryoablation combined with Camrelizumab monoclonal antibody in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(6): 1169-1174. doi: 10.12449/JCH240616
    [7]Xiaohua ZHANG, Ying FENG, Xianbo WANG. Role of the Hedgehog signaling pathway in hepatocellular carcinoma and its tumor microenvironment[J]. Journal of Clinical Hepatology, 2024, 40(4): 822-827. doi: 10.12449/JCH240429
    [8]Tingting SHI, Runbing ZHANG, Yang WU, Yani ZHANG, Lingling ZHU, Chun GAO, Jingjing JIANG, Xiaofeng ZHENG, Jiucong ZHANG. Role of extracellular vesicles of different origins in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(6): 1264-1268. doi: 10.12449/JCH240630
    [9]Shichun LU. Challenges and reflections on conversion therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1738-1740. doi: 10.12449/JCH240904
    [10]Chi MA, Guang TAN. Strategies and practice of conversion therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1725-1731. doi: 10.12449/JCH240902
    [11]Runbing ZHANG, Tingting SHI, Yang WU, Jiucong ZHANG, Xiaofeng ZHENG. The mechanism of autophagy inducing drug resistance of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(11): 2315-2319. doi: 10.12449/JCH241128
    [12]Xiaomeng YAO, Keke SUN, Yunkai LIN, Hui WANG, Liwei DONG, Lei CHEN, Heping HU. Molecular mechanism of lenvatinib resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2524-2530. doi: 10.12449/JCH241225
    [13]Hongxia LI, Yimeng SUN, Hongtao ZHANG, Shuwang HAN, Delin ZHANG, Haitao SHANG, Wu GUO, Junjian LIU, Zhonglian LI. Role of HBV DNA polymerase in mediating the immune escape of tumor cells in HBV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(12): 2858-2866. doi: 10.3969/j.issn.1001-5256.2023.12.017
    [14]Chun GAO, Jingjing JIANG, Yuchun CHEN, Xiaohui YU, Jiucong ZHANG, . Mechanism of action of N7-methylguanosine in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(12): 2946-2951. doi: 10.3969/j.issn.1001-5256.2023.12.029
    [15]Liver Oncology Branch, China Association for the Promotion of International Exchange in Healthcare, Immunology Branch. Chinese expert consensus on targeted immunotherapy combined with local therapy for advanced hepatocellular cancer[J]. Journal of Clinical Hepatology, 2023, 39(12): 2782-2792. doi: 10.3969/j.issn.1001-5256.2023.12.006
    [16]Quan ZHOU, Chunlin CAI, Jinqiang LI. Gut-liver axis： Intestinal microbial homeostasis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2710-2717. doi: 10.3969/j.issn.1001-5256.2023.11.029
    [17]Zhisong NI, Junhan WEN, Weiwei ZHAO, Shoujun YU, Liang HAO, Yu CHENG, Xin LIU. Neoadjuvant therapy for hepatocellular carcinoma： Current situation and prospects[J]. Journal of Clinical Hepatology, 2023, 39(11): 2697-2704. doi: 10.3969/j.issn.1001-5256.2023.11.027
    [18]Pengwei REN, Ying HAN, Xinmin ZHOU. Predictive indicators for the efficacy of targeted therapy/immunotherapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2705-2709. doi: 10.3969/j.issn.1001-5256.2023.11.028
    [19]Shisi LI, Zhitang GUO, Zhangbin CHEN, Yishan TENG. Research advances in systemic therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(12): 2943-2946. doi: 10.3969/j.issn.1001-5256.2021.12.044
    [20]Liang Yuan, Wang ShiMing, Shi ZhenMing. Research advances in application of molecular- targeted therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(3): 601-604. doi: 10.3969/j.issn.1001-5256.2016.02.03.045
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(4)

    1. 张雪娇，李欣欣，李磊，王然. 多种系统评分对肝硬化合并急性上消化道出血患者28 d死亡的预测作用. 现代消化及介入诊疗. 2024(05): 523-527 .
    2. 元媛，毛永武，张雪梅，田爱平，王晓锋. 肝硬化并上消化道出血急救预后危险因素研究. 中华灾害救援医学. 2024(06): 690-692 .
    3. 胡晓翠，李鹏，汝童，王裕麟，刘庆. 肝硬化上消化道出血患者血清血小板生成素、前列腺素E2水平与病情严重程度和预后的关系. 传染病信息. 2024(06): 487-491 .
    4. 罗方杰，汤小玉，陈莉，魏董丹，程玲，罗卿，杨洪英. 慢性乙肝患者ALBI、PALBI评分与肝纤维化分期、炎症分级的关系分析. 保健医学研究与实践. 2024(10): 69-74 .

    Other cited types(1)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (584) PDF downloads(100) Cited by(5)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2784]YesterdayPV[4482]TodayIP[112]TodayPV[168]Online[48]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return